Regeneron Pharmaceuticals, Inc. ( REGN) – Advances across therapeutic areas

Regeneron Pharmaceuticals, Inc. (REGN) (Q2FY23)

Stock Performance – Regeneron Pharmaceuticals stock price showed an upward trend in the past 3 months. It gave 10.55% returns during the period. The stock price increased by 17.28% in the past 1 year. The stock has a 52-week high of $847.50 and its 52-week low is $668.00.

In the past 3 years, the stock has increased by 53.01%. REGN has a 50-day moving Avg. and 200-day moving Avg. of $781.47 and $763.94, respectively.

Revenue Performance – REGN revenues increased 11% to $3.16bn versus second quarter 2022. Total revenue increased to $6.32bn in 1HFY23 compared to $5.82bn in 1HFY22.

Company Guidance for FY23 – REGN expect GAAP R&D of $4.315– $4.455 billion, GAAP SG&A of $2.540–$2.680bn, GAAP gross margin on net product sales of 87%–89%.

The company expects Capital expenditures of $760–$830mn, a GAAP effective tax rate of 8%–9%. On a Non-GAAP basis, R&D of $3.825–$3.925bn, $2.180–$2.280bn, effective tax rate of 10%–11% for FY23.

Highlights

The distinctive flexibility of an internally developed pharmaceutical pipeline is a catalyst for the creation of novel and distinct therapeutic combinations. This adaptability enables REGN to explore innovative treatment pairings that might not have been envisioned before.

This report is useful for M&A, business & investment analysis to all students, researchers, investors, private equity houses, broking firms, hedge funds, advisory firms and corporates to decide upon their investment strategies. Do connect with us, if you are looking for equity valuation, recommendation, analysis and market recommendation for any specific company, sector and industry.

Highlights

Valuation

– Enterprise Value
– CrispIdea Forecast
– Drug Sales (Actual)
– Drug Sales (Forecasted)
– Economic Value Added Analysis
– P/E Analysis
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum

Actual & Historical Performance

– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– Key Developments
– M&A

Peer Performance

– Summary
– Profitability
– Growth
– Price Performance

Ownership

Stock Price Performance

Crispidea Coverage

No of Pages: 37

To download the previous quarter’s equity/report CLICK HERE

To Download other equity/reports CLICK HERE

Follow our LinkedIn page for more updates.